International Clinical Trial: A single-arm, phase II, exploratory study of Culmerciclib in combination with letrozole and dual HER2 blockade with trastuzumab and pertuzumab as neoadjuvant therapy for HR-positive/HER2-positive breast cancer

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131713) titled 'A single-arm, phase II, exploratory study of Culmerciclib in combination with letrozole and dual HER2 blockade with trastuzumab and pertuzumab as neoadjuvant therapy for HR-positive/HER2-positive breast cancer' on Sept. 6.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: WeiHai Municipal Hospital

Condition: Breast cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-09-07

Target Sample Size: Experimental group:28;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=315643

Published by HT Digital C...